ALNOV:EPA
Novacyt SA
€0.46
arrow_upward
+0.22%(+0.00100) 1D
Oct 21, 2:52:42 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNOV...
Open
€0.46
High
€0.46
Low
€0.46
Mkt. cap
33.65M
Avg. vol.
235.63K
Volume
12.57K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.37
Shares outstanding
72.59M
No. of employees
228
Open
€0.46
High
€0.46
Low
€0.46
Mkt. cap
33.65M
Avg. vol.
235.63K
Volume
12.57K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.37
Shares outstanding
72.59M
No. of employees
228
News stories
From web sources and news partners
Forbes
·
20 minutes ago
Tech Accounts For 40% Of The S&P 500. Here Are Three Risks To Watch.
TradingView
·
40 minutes ago
The Dow Jones Index Opens 0.01% Higher
StoneX
·
17 minutes ago
S&P 500 Forecast: SPX rises after SpaceX jumps, Meta up next
BeInCrypto
·
4 hours ago
Is Bitcoin on the Verge of a Deeper Correction? The S&P 500 May Hold the Answer
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA